Cargando…

Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis

The interaction between intestinal microecological dysregulation, altered inflammatory factors, and cirrhosis is unclear. The aim of this systematic review and meta-analysis was to synthesize the results of previous studies to assess the efficacy of probiotics in the treatment of cirrhosis and their...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Qinglan, Lei, Yumeng, Wang, Jiadun, Wang, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590617/
https://www.ncbi.nlm.nih.gov/pubmed/37872967
http://dx.doi.org/10.1515/biol-2022-0741
_version_ 1785124027672559616
author Xia, Qinglan
Lei, Yumeng
Wang, Jiadun
Wang, Qiang
author_facet Xia, Qinglan
Lei, Yumeng
Wang, Jiadun
Wang, Qiang
author_sort Xia, Qinglan
collection PubMed
description The interaction between intestinal microecological dysregulation, altered inflammatory factors, and cirrhosis is unclear. The aim of this systematic review and meta-analysis was to synthesize the results of previous studies to assess the efficacy of probiotics in the treatment of cirrhosis and their effect on inflammatory factors, as well as to explore the relationship between gut microecological dysregulation and liver disease to gain a deeper understanding of this interaction. Up to December 2022, eligible studies were identified by searching the following databases: National Knowledge Infrastructure (CNKI), Wanfang Data, Web of Science, PubMed, Embase, Medline, and the Cochrane Library. Statistical analysis was performed using software RevMan Version 5.4. A total of 33 eligible randomized controlled trials were included in the study, and data on probiotic strains, duration of intervention, measures in the control group, and outcomes were extracted and evaluated. Compared to the control group, the experimental group had significant improvements in overall efficacy. The results of the meta-analysis revealed that probiotic use significantly decreased biochemical parameters for liver function, including aspartate transaminase, alanine aminotransferase, and total bilirubin. Similar result was obtained in interleukin-6, tumor necrosis factor-α, and endotoxin. However, probiotic intervention did not significantly affect interleukin-2 and interleukin-10. The current meta-analysis illustrates that probiotic supplementation reduces inflammatory markers and biochemical parameters for liver function in patients with cirrhosis, suggesting that probiotic management may be a novel treatment for cirrhosis. Furthermore, the interaction of the gut microbiota, associated metabolites, and inflammation factors with cirrhosis may provide a promising therapeutic target for the pharmacological and clinical treatment of cirrhosis.
format Online
Article
Text
id pubmed-10590617
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-105906172023-10-23 Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis Xia, Qinglan Lei, Yumeng Wang, Jiadun Wang, Qiang Open Life Sci Review Article The interaction between intestinal microecological dysregulation, altered inflammatory factors, and cirrhosis is unclear. The aim of this systematic review and meta-analysis was to synthesize the results of previous studies to assess the efficacy of probiotics in the treatment of cirrhosis and their effect on inflammatory factors, as well as to explore the relationship between gut microecological dysregulation and liver disease to gain a deeper understanding of this interaction. Up to December 2022, eligible studies were identified by searching the following databases: National Knowledge Infrastructure (CNKI), Wanfang Data, Web of Science, PubMed, Embase, Medline, and the Cochrane Library. Statistical analysis was performed using software RevMan Version 5.4. A total of 33 eligible randomized controlled trials were included in the study, and data on probiotic strains, duration of intervention, measures in the control group, and outcomes were extracted and evaluated. Compared to the control group, the experimental group had significant improvements in overall efficacy. The results of the meta-analysis revealed that probiotic use significantly decreased biochemical parameters for liver function, including aspartate transaminase, alanine aminotransferase, and total bilirubin. Similar result was obtained in interleukin-6, tumor necrosis factor-α, and endotoxin. However, probiotic intervention did not significantly affect interleukin-2 and interleukin-10. The current meta-analysis illustrates that probiotic supplementation reduces inflammatory markers and biochemical parameters for liver function in patients with cirrhosis, suggesting that probiotic management may be a novel treatment for cirrhosis. Furthermore, the interaction of the gut microbiota, associated metabolites, and inflammation factors with cirrhosis may provide a promising therapeutic target for the pharmacological and clinical treatment of cirrhosis. De Gruyter 2023-10-17 /pmc/articles/PMC10590617/ /pubmed/37872967 http://dx.doi.org/10.1515/biol-2022-0741 Text en © 2023 the author(s), published by De Gruyter https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Review Article
Xia, Qinglan
Lei, Yumeng
Wang, Jiadun
Wang, Qiang
Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis
title Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis
title_full Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis
title_fullStr Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis
title_full_unstemmed Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis
title_short Probiotic management and inflammatory factors as a novel treatment in cirrhosis: A systematic review and meta-analysis
title_sort probiotic management and inflammatory factors as a novel treatment in cirrhosis: a systematic review and meta-analysis
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590617/
https://www.ncbi.nlm.nih.gov/pubmed/37872967
http://dx.doi.org/10.1515/biol-2022-0741
work_keys_str_mv AT xiaqinglan probioticmanagementandinflammatoryfactorsasanoveltreatmentincirrhosisasystematicreviewandmetaanalysis
AT leiyumeng probioticmanagementandinflammatoryfactorsasanoveltreatmentincirrhosisasystematicreviewandmetaanalysis
AT wangjiadun probioticmanagementandinflammatoryfactorsasanoveltreatmentincirrhosisasystematicreviewandmetaanalysis
AT wangqiang probioticmanagementandinflammatoryfactorsasanoveltreatmentincirrhosisasystematicreviewandmetaanalysis